Malaria:
Indications for: ARAKODA
Malaria prophylaxis.
Adult Dosage:
Swallow whole. Take with food. ≥18yrs: initially 200mg once daily starting 3 days before travel, then 200mg once weekly starting 7 days after last loading dose while in endemic area, then 200mg taken once, 7 days after last maintenance dose.
Children Dosage:
<18yrs: not established.
ARAKODA Contraindications:
G6PD deficiency or unknown status. Nursing mothers when infant is G6PD deficient or status unknown. History of or current psychotic disorders.
ARAKODA Warnings/Precautions:
Must test for G6PD deficiency prior to initiation. Monitor for hemolysis; discontinue if occurs. NADH-dependent methemoglobin reductase deficiency; monitor and discontinue if signs of methemoglobinemia occur. Consider discontinuing if psychotic symptoms (eg, hallucinations, delusions, disorganized thinking/behavior) occur. Discontinue if hypersensitivity reactions occur. Renal or hepatic impairment: monitor. Exclude pregnancy status prior to initiation. Pregnancy: not recommended; if detected during therapy, discontinue and switch to alternatives. Advise females of reproductive potential to use effective contraception during and for 3 months after last dose. Nursing mothers: not recommended (during and for 3 months after last dose) in G6PD-deficient infant or status unknown.
ARAKODA Classification:
Aminoquinoline.
ARAKODA Interactions:
Avoid concomitant OCT2 and MATE substrates (eg, dofetilide, metformin); if unavoidable, monitor and consider dose reduction of substrate if needed.
Adverse Reactions:
Headache, dizziness, back pain, diarrhea, nausea, vomiting, increased ALT, motion sickness, insomnia, depression, abnormal dreams, anxiety; hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Tabs—16
